This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prenetics Global Limited (PRE) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Prenetics Global Limited (PRE). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Wall Street Analysts See Prenetics Global Limited (PRE) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Prenetics Global Limited (PRE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Prenetics Global Limited (PRE) Stock Moves -1.14%: What You Should Know
by Zacks Equity Research
In the latest trading session, Prenetics Global Limited (PRE) closed at $0.87, marking a -1.14% move from the previous day.
Should You Invest in Prenetics Global Limited (PRE) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Prenetics Global Limited (PRE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Prenetics Global Limited (PRE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Prenetics Global Limited (PRE) closed at $0.93 in the latest trading session, marking a +1.98% move from the prior day.
Prenetics Global Limited (PRE) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Prenetics Global Limited (PRE) closed the most recent trading day at $0.89, making no change from the previous trading session.
Prenetics Global Limited (PRE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Prenetics Global Limited (PRE) closed at $0.85 in the latest trading session, marking a +0.01% move from the prior day.
Wall Street Analysts Look Bullish on Prenetics Global Limited (PRE): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Prenetics Global Limited (PRE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Prenetics Global Limited (PRE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Prenetics Global Limited (PRE) closed at $0.79 in the latest trading session, marking a -1.89% move from the prior day.
Prenetics Global Limited (PRE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Prenetics Global Limited (PRE) closed at $0.82 in the latest trading session, marking a +0.91% move from the prior day.
Prenetics Global Limited (PRE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Prenetics Global Limited (PRE) closed at $0.83 in the latest trading session, marking a -0.59% move from the prior day.
4 Medical Stocks to Buy as Rate Hike Cycle Nears End
by Indrajit Bandyopadhyay
We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.
Prenetics Global Limited (PRE) Loses -24.21% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Prenetics Global Limited (PRE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
3 P&C Insurers to Protect Your Portfolio This Earnings Season
by Zacks Equity Research
The final quarter of 2014 escaped the miseries of huge catastrophe losses.